



MEDIA RELEASE

MEDIA RELEASE

MEDIA RELEASE

MEDIA RELEASE

## **Proteon Therapeutics Adds Experienced Research and Drug Development Talent to Its Team**

### **FOR IMMEDIATE RELEASE**

BOSTON and KANSAS CITY, Mo., (Sept. 12, 2006) — Three top pharmaceutical executives and a senior scientist have joined Proteon Therapeutics, Inc., to help guide the biotechnology company as it develops its novel, first-in-class products for patients with renal failure and vascular diseases. Proteon announced today the following hires: Steven K. Burke, M.D., senior vice president and chief medical officer; Martha J. Carter, RAC, senior vice president of regulatory affairs and quality assurance; Joseph E. Tyler, vice president of manufacturing; and Marco D. Wong, M.D., Ph.D., physician-scientist.

“With the addition of Steven, Martha, Joe, and Marco, we have significantly strengthened our team in the important areas of research and development. Proteon is now well positioned to continue development of our technology and our business plan,” said Timothy P. Noyes, president and CEO of Proteon Therapeutics, Inc.

The new hires come following the \$19 million raised in the Series A venture capital round from TVM Capital, Skyline Ventures, Prism Venture Partners, and Intersouth Partners.

**Steven K. Burke, M.D.**, was previously senior vice president of medical and regulatory affairs at Genzyme Drug Discovery and Development. Prior to Genzyme, Burke was the vice president of clinical research at GelTex Pharmaceuticals. At GelTex and Genzyme, he obtained broad experience in all phases of drug development, from IND to NDA approval, including post-approval outcomes studies. Burke began his career as an associate director at Glaxo, Inc., where he worked on two drugs that were eventually approved in the United States.

Burke has a bachelor’s degree from Harvard College and holds a medical degree from Cornell University Medical College.

**Martha J. Carter, RAC**, is a 29-year veteran of the pharmaceutical industry and formerly served as the senior vice president of regulatory affairs at Trine Pharmaceuticals, Inc. There she was responsible for the company’s worldwide regulatory function. Prior to Trine Pharmaceuticals, Carter served as vice president of regulatory affairs at GelTex Pharmaceuticals, Inc., leading the company’s regulatory and quality assurance/quality control functions for both commercial and investigational drug products.

Carter has broad regulatory affairs experience in prescription drugs and medical devices, and in bringing products from the pre-IND stage through approval and commercialization. She has a bachelor’s degree from Northeastern University and completed postgraduate studies at Massachusetts College of Pharmacy and Health Sciences.

-MORE-

**Joseph E. Tyler** brings 33 years of manufacturing experience including small molecules, proteins, and medical devices. Previously, Tyler served as the principal for PharmSupply, where he was a pharmaceutical consultant for sourcing, supply chain management, manufacturing compliance, CMC regulatory filing preparation and review, and management of drug development programs. He has served as the vice president of manufacturing for Momenta Pharmaceuticals and the vice president of operations for Salix Pharmaceuticals.

Tyler holds a graduate degree in chemical engineering from Carnegie Mellon University and a Master of Science degree in biochemical engineering from Cornell University.

**Marco D. Wong, M.D., Ph.D.**, has joined Proteon Therapeutics as a physician-scientist. Wong most recently served as a post-doctoral research associate at the Stowers Institute for Medical Research. Prior to working at Stowers, Wong was a post-doctoral fellow in the Department of Biochemistry and Molecular Biology at Wayne State University School of Medicine in Detroit, where he was the team leader of the metalloregulatory protein group. Wong also received his M.D. from Wayne State, and completed a Ph.D. during his general surgery residency.

#### **About Proteon Therapeutics**

Proteon Therapeutics is a biopharmaceutical company developing PRT-201, a novel human recombinant protein that permanently dilates segments of blood vessels, blocks vasospasm, and reduces the formation of vascular scarring. This unique combination of features is crucial for improving both the immediate and long-term success of hemodialysis access, bypass graft, and angioplasty procedures. The company's venture capital investors include TVM Capital ([www.tvm-capital.com](http://www.tvm-capital.com)), Skyline Ventures ([www.skylineventures.com](http://www.skylineventures.com)), Prism Venture Partners ([www.prismventure.com](http://www.prismventure.com)), and Intersouth Partners ([www.intersouth.com](http://www.intersouth.com)). For more information about Proteon, visit [www.proteontherapeutics.com](http://www.proteontherapeutics.com).

###

#### **COMPANY CONTACT:**

Timothy Noyes  
President & CEO  
[tnoyes@proteontherapeutics.com](mailto:tnoyes@proteontherapeutics.com)

#### **PRESS CONTACT:**

Holly Gibson  
Fleishman-Hillard  
816-512-2349  
[gibsonh@fleishman.com](mailto:gibsonh@fleishman.com)